乐动体育


Jun Zhu, MD, PhD  with Beijing University Cancer Hospital Principal Investigator for Brukinsa

Jun Zhu, MD, PhD with Beijing University Cancer Hospital Principal Investigator for Brukinsa

Recently, BeiGene Ltd’s lymphoma treatment Brukinsa was approved by the U.S. Food and Drug Administration. This is the first time a drug developed predominantly in China by a Chinese biopharma sponsor has been approved within America. The key clinical trials...
Acalabrutinib(Calquence) Monotherapy Active in Waldenstrom Macroglobulinemia in Phase II—More Study Needed

Acalabrutinib(Calquence) Monotherapy Active in Waldenstrom Macroglobulinemia in Phase II—More Study Needed

Led by Dr. Roger G. Owen, St. James’ University Hospital, Leeds, UK, and colleagues recently concluded that for those patients with treatment-naïve or relapsed/refractory Waldrenstrom Macroglobulinemia (WM), a type of non-Hodgkin lymphoma, single-agent acalabrutinib...

Pin It on Pinterest